Ekf Diagnostics Share Discussion Threads

[hastings] 05/8/2020 07:21

PUG, if you read my recent interview with the CEO, testing is going to required even after a vaccine and he felt (his opinion) that a vaccine was realistically a year away.

[epicsurf] 05/8/2020 07:19

Particularly like the the statement a initial order of 3 million implying
More to come,

[pugugly] 05/8/2020 07:18

Very rarely see anything like this in a rns

"Due to the continued demand for PrimeStore MTM, full year performance is likely to further exceed, and possibly significantly exceed, previously revised management expectations."

BUT - What happens to revenue when and IF a vaccine is available - or will it keep growing as some experts suggest COVID will be with us for years -

OR - will the technology be by-passed by new rapid point of care tests when available?

Whatever should be a very blue day - Keep safe everyone!

[epicsurf] 05/8/2020 07:06

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has received an initial order worth £3m from a partner from the private sector to supply PrimeStore MTM, a novel patented sample collection device, to be used in a COVID-19 testing programme for UK staff. This new supply contract is in addition to the $14.1m orders for the three-month period ending 30 September 2020, already disclosed in the 14 July 2020 update, and also covers the period ending 30 September 2020.

 

With increasing orders for the PrimeStore MTM sample collection device the Company has now established a second UK production line at the Company's facilities in South Wales. EKF now employs 20 new contracting staff members to work on these production lines, which are able to produce 25,000 sample collection tubes a day. Further details on the expansion of manufacturing capacity was provided in the 14 July 2020 update and the Company can confirm that the PrimeStore MTM production line is now up and running in Germany.

 

The PrimeStore MTM sample collection device, deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, greatly reducing risk of infection. The device was invented in 2006 in preparation for a worldwide pandemic and is designed to de-activate pathogen rapidly and stabilise the RNA for up to four weeks with no requirement for cold storage. In the case of COVID-19, by deactivating the virus testing can now take place outside of containment facilities opening up capacity in more testing laboratories. With the flu season approaching, the PrimeStore MTM can also safely collect flu and COVID-19 samples in the same collection kit.

 

Due to the continued demand for PrimeStore MTM, full year performance is likely to further exceed, and possibly significantly exceed, previously revised management expectations.

 

 

[wan] 05/8/2020 07:06

Yes, another excellent update, and (unfortunately) the tail winds continue to grow in strength!

[hastings] 05/8/2020 07:04

Excellent news this morning.Wasn't sure whether Craven Cottage had received a vision or was referring to Fulham's return!!

[cravencottage] 04/8/2020 23:14

onwards and upwards!!!!!!!!!!!!

[apatel21] 04/8/2020 14:32

You can sell in significant size at 50p nowI think this ready to move higher now

[masurenguy] 04/8/2020 09:03

The RENX shareprice has tripled in the past 4 months so the EKF 4.5% holding is now worth £15.7m.

[wan] 04/8/2020 08:14

I should have added that the 30 minute readout time could be reduced by at least 5 minutes by using PrimeStore MTM

[wan] 04/8/2020 08:01

Given the recent news flow regarding RT-LAMP. For readers interest, there is scientific evidence to suggest that an RT-LAMP assay for the SARS-CoV-2 virus can be made even more sensitive by an inactivation and purification scheme and provides a readout in as little as 30 minutes. What has piqued my interest, is that PrimeStore MTM eliminates the inactivation process and furthermore uses less reagent.

(For further reading see post 258)

[cravencottage] 03/8/2020 09:48

Malc

Very re-assuring....

Given the uncertainties at the moment this is one stock i'm able to sleep very well at night with..

[malcolmmm] 03/8/2020 08:22

CravenCottage2 Aug '20 - 22:30 - 335 of 337
0 0 0
Do Techinvest offer any target price Malc?

Was the issue out this W/E?Y

No they don't give a target and the issue was out on the weekend.
Quite a comprefensive positive write up .They have recommended 'Keep Buying for the last two months which is unusual. usually a 'Strong Hold' recommendation

[buywell3] 03/8/2020 08:07

Nanopore News

[wan] 03/8/2020 08:00

Today's rapid test developments/announcements demonstrates that whether testing is PCR, antigen, antibody, lab or point of care, expect a significant increase in testing globally, and especially as we enter the autumn to get us anywhere near being back to normal!

I note that EKF Germany are currently recruiting (on a three shift basis) for the operation of 24 hour production (not sure what it specifically relates to at this stage).

[cravencottage] 02/8/2020 22:30

Do Techinvest offer any target price Malc?

Was the issue out this W/E?

Cheers

[malcolmmm] 02/8/2020 19:09

Techinvest- Keep Buying

[bones] 31/7/2020 08:20

Key features

Specific for glycated albumin (GA)
Measures both glycated albumin and total albumin in separate reactions
Standarized to an established reference (JCCRM611)
Widely published method
Exclusive to EKF Diagnostics in the US

[bones] 30/7/2020 22:12

Tweeted a few hours ago by EKF:

The Lucica® method for Glycated Albumin (GA), manufactured by Asahi Kasei Pharma Corporation, is a specific test for GA that is now FDA cleared for sale in the U.S.

[cravencottage] 30/7/2020 20:54

You're not the only one Malcolm .

I picked up a few myself today ;-)

[marvelman] 30/7/2020 08:33

You obviously don't like round numbers Malcom :-))

[malcolmmm] 30/7/2020 08:30

Looks like I am the only one topping up this morning, so far

[retirementfund] 30/7/2020 08:23

54p will be past no doubt about it I wouldn't be surprised to see this past £1 before turn of the year. This company will be making serious profits now. I think the market is ignoring the fact that we had orders at June covering to September but looking at it we were picking them up at a rate of circa $4m a month. This share has everything, strong cash position, pays a dividend, access to a basket of new technologies, investment listing on Nasdaq and potentially more to follow.

All in my view

[mirandaj] 29/7/2020 16:39

Wondering if Longhorn will have increased its total and by how much since this when they had 11.4% of the potential total for the DHS USA - 16th June. It might reflect on the demand here.

wan highlighted this some weeks ago.

"25. Longhorn Vaccines and Diagnostics LLC


• Max. value of contracts won during COVID-19: $225.8 million


• Largest federal agency customer: Department of Homeland Security ($225.8 million)


• Total amount paid to date: $25.8 million (11.4% of potential total)


• Industry: Diagnostic supplies


Longhorn Vaccines and Diagnostics is a veteran-owned company that develops products for molecular testing. During the COVID-19 pandemic, the company's PrimeStore Molecular Transport Medium, which was invented in 2006, has proven invaluable as it can rapidly inactivate the virus and allow molecular testing outside containment facilities, increasing therefore the number of testing laboratories. The company was awarded a contract with the DHS that could be worth as much as $225.8 million."

[hastings] 29/7/2020 12:37

I think the shareS have hit 54p over the last year riv, but I'd be surprised if that isn't seen off before too long.
With Germany up and running (PrimeStore) as Europe sees increasing cases and the UK now also ramping up there should be plenty of upside.

Worth checking out the SourceBioscience site and taking a look at the links below.

SourceBioscience (I used to hold and did ok) has a very strong and increasing relationship with the NHS and the private sector, so a good route for EKF.